NEW YORK (Reuters Health) – Bevacizumab improved visual acuity and
Bevacizumab an Option for Diabetic Macular Edema
NEW YORK (Reuters Health) – Bevacizumab improved visual acuity and
Could Tamoxifen Dose Be Slashed Down to 2.5 mg?
Tamoxifen has long been used in breast cancer, both in
Tocilizumab Scores FDA Approval for SSc-ILD
The Food and Drug Administration has approved subcutaneously-injected tocilizumab (Actemra)
EU Investigating Teva for Blocking Rivals to Multiple Sclerosis Drug
BRUSSELS (Reuters) – Israeli drugmaker Teva is being investigated by
Anthracycline-Free Neoadjuvant Regimen Safe, Effective for TNBC
For patients with triple-negative breast cancer (TNBC), neoadjuvant carboplatin plus
CAR T-cell Products Shine, Reveal New Insights
Real-world experience with chimeric antigen receptor (CAR) T-cell therapies for
Combo Shows ‘Impressive’ Survival Results in First-Line RCC
The combination of lenvatinib and pembrolizumab outperforms sunitinib as first-line